Protease-activated receptor 2: a promising therapeutic target for women's cancers
H Shah, DP Fairlie, J Lim - The Journal of Pharmacology and Experimental …, 2024 - Elsevier
Cancers affecting women, such as breast, uterine, ovarian, endometrial, and cervical
cancers, have become increasingly prevalent. The growing incidence and death rates …
cancers, have become increasingly prevalent. The growing incidence and death rates …
New Target (s) for RNF43 Regulation: Implications for Therapeutic Strategies
JK Nag, P Appasamy, H Malka… - International …, 2024 - pmc.ncbi.nlm.nih.gov
Cancer cells depend on specific oncogenic pathways or present a genetic alteration that
leads to a particular disturbance. Still, personalized and targeted biological therapy remains …
leads to a particular disturbance. Still, personalized and targeted biological therapy remains …
Synthesis and mechanism of action of new purine derivatives against triple negative breast cancer
Q Zhang, G Sun, Y Huang, S Cui, T Li, L Zhao… - European Journal of …, 2023 - Elsevier
Triple negative breast cancer (TNBC) is considered to be the most difficult subtype of breast
cancer to treat because of its extremely prone to metastasis and the lack of targeted therapy …
cancer to treat because of its extremely prone to metastasis and the lack of targeted therapy …
Discovery of Protease-activated receptor 2 antagonists derived from phenylalanine for the treatment of breast cancer
T Kim, Y Lee, H Lim, Y Kim, H Cho, W Namkung… - Bioorganic …, 2024 - Elsevier
Abstract Protease-activated receptor 2 (PAR2) has garnered attention as a potential
therapeutic target in breast cancer. PAR2 is implicated in the activation of extracellular …
therapeutic target in breast cancer. PAR2 is implicated in the activation of extracellular …
[HTML][HTML] PH-binding motifs as a platform for drug design: Lessons from protease-activated receptors; PARs
While targeted cancer therapy is greatly dependent on specific oncogenic pathways or
conferred by genetic alterations, it remains yet challenging and somewhat disappointing …
conferred by genetic alterations, it remains yet challenging and somewhat disappointing …
[HTML][HTML] Integrative multiomics analysis identifies a metastasis-related gene signature and the potential oncogenic role of EZR in breast cancer
G Xiao, F Cheng, J Yuan, W Lu, P Wang… - Oncology …, 2022 - ncbi.nlm.nih.gov
Distant metastasis is a major cause of increased mortality in breast cancer patients, but the
mechanisms underlying breast cancer metastasis remain poorly understood. In this study …
mechanisms underlying breast cancer metastasis remain poorly understood. In this study …